ClinConnect ClinConnect Logo
Search / Trial NCT06545435

Predicting Appendicular Lean and Fat Mass With Bioelectrical Impedance Analysis Among Adult Patients With Obesity.

Launched by UNIVERSITY OF ROMA LA SAPIENZA · Aug 5, 2024

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Appendicular Lean Mass Fat Mass Body Composition Bio Impedance Analysis

ClinConnect Summary

This clinical trial is focused on improving how we measure body composition in adults with obesity, specifically looking at the amounts of fat and lean tissue in their bodies. Researchers want to create new equations using a method called bioelectrical impedance analysis (BIA), which uses a small electrical current to estimate body composition. They will compare these new equations with existing methods and validate them using other imaging techniques like dual-energy X-ray absorptiometry (DXA) and magnetic resonance imaging (MRI).

To participate, you need to be an adult aged 18 or older with obesity (a body mass index or BMI of 30 or higher). You should also have previous DXA and BIA measurements available and be willing to give consent for your data to be used. However, there are some exclusions, such as having certain chronic diseases, being very physically active, or being pregnant. Participants will help improve the accuracy of body composition assessments, which could lead to better health management in the future. If you decide to join, you can expect to undergo some measurements and tests that will help advance our understanding of obesity.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adults with obesity (BMI ≥ 30 kg/m²)
  • Age 18 years and older
  • Available baseline DXA and BIA measurements
  • Provided informed consent for data use
  • Exclusion Criteria:
  • any chronic disease or medication that can significantly affect body composition \[eg. malignant diseases in the last 5 years, organ failure, acute inflammation (C-reactive protein\>10 mg/L) autoimmune diseases, neurological diseases, syndromic obesity\]
  • cognitive impairment (Mini-Mental State Examination \<25)
  • subjects that are considered physically active (athletes or very active subjects i.e., performing at least 150 minutes of moderate to vigorous physical activity per week)
  • alcohol intake \>140g/wk for Males and 70g/wk for Females
  • participation in a weight-reducing program (last 3 months)
  • impossibility to perform DXA exam
  • pregnancy and breast-feeding.

About University Of Roma La Sapienza

The University of Roma La Sapienza, one of Italy's premier research institutions, is dedicated to advancing medical science and improving patient outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses its extensive expertise in diverse fields, including medicine, biotechnology, and public health, to conduct rigorous and ethically sound research. Committed to fostering educational excellence and promoting groundbreaking discoveries, La Sapienza actively engages in clinical trials that aim to address critical health challenges and contribute to the development of new therapeutic interventions.

Locations

Baton Rouge, Louisiana, United States

Chapel Hill, North Carolina, United States

Perth, , Australia

Pelotas, Rio Grande Do Sul, Brazil

Edmonton, Alberta, Canada

Cagliari, , Italy

Roma, , Italy

Trieste, , Italy

Lisboa, , Portugal

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported